Payment overview · 2025
General Payments
$346.89
22 reported records · 5 companies
Healthcare provider profile · identity verified
Stephanie Keesee, APRN-CNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HOLDENVILLE, OK · NPI 1699150052
Verified facts
What the public records show
CMS Open Payments records show Stephanie Keesee, APRN-CNP received $346.89 in general payments during 2025 across 22 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 54.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $189.08 | 54.5% | 15 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $93.22 | 26.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.91 | 9.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.55 | 4.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.13 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $346.89 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $120.34 | 12 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $93.22 | 3 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $50.80 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 191 | 48 |
| Prednisone | Prednisone | 156 | 123 |
| Azithromycin | Azithromycin | 134 | 105 |
| Tramadol Hcl | Tramadol Hcl | 127 | 31 |
| Ozempic | Semaglutide | 109 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 100 | 79 |
| Omeprazole | Omeprazole | 98 | 41 |
| Promethazine Hcl | Promethazine Hcl | 90 | 64 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 89 | 21 |
| Lisinopril | Lisinopril | 86 | 30 |
| Meloxicam | Meloxicam | 83 | 27 |
| Montelukast Sodium | Montelukast Sodium | 81 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 78 | 31 |
| Mounjaro | Tirzepatide | 73 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 72 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 38 |
| Amoxicillin | Amoxicillin | 63 | 48 |
| Losartan Potassium | Losartan Potassium | 61 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 46 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 42 |
| Alprazolam | Alprazolam | 59 | suppressed |
| Metformin Hcl | Metformin Hcl | 58 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 28 |
| Potassium Chloride | Potassium Chloride | 56 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 16 |
| Atorvastatin Calcium | Atorvastatin Calcium | 54 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 30 |
| Ibuprofen | Ibuprofen | 51 | 29 |
| Cephalexin | Cephalexin | 48 | 29 |
| Ondansetron Odt | Ondansetron | 48 | 26 |
| Allopurinol | Allopurinol | 40 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 40 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 39 | 11 |
| Celecoxib | Celecoxib | 38 | 15 |
| Donepezil Hcl | Donepezil Hcl | 37 | 12 |
| Furosemide | Furosemide | 37 | 16 |
| Buspirone Hcl | Buspirone Hcl | 36 | 19 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Fluconazole | Fluconazole | 32 | 20 |
| Clindamycin Hcl | Clindamycin Hcl | 30 | 21 |
| Eliquis | Apixaban | 30 | suppressed |
| Simvastatin | Simvastatin | 30 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 26 | suppressed |
| Ofloxacin | Ofloxacin | 26 | 21 |
| Sertraline Hcl | Sertraline Hcl | 25 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 20 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 23 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 23 | 13 |
| Carvedilol | Carvedilol | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 20 |
| Estradiol | Estradiol | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Lorazepam | Lorazepam | 18 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Constulose | Lactulose | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Topiramate | Topiramate | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Cefdinir | Cefdinir | 13 | 11 |
| Lacosamide | Lacosamide | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $346.89 · 22 records | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, Korlym, QULIPTA, REXULTI, Saxenda, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error